Agilon Health (NYSE:AGL) Announces Quarterly Earnings Results, Beats Estimates By $3.20 EPS

Agilon Health (NYSE:AGL) announced its earnings results on Wednesday. The company reported $1.97 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.23) by $3.20, FiscalAI reports. The business had revenue of $1.52 billion during the quarter, compared to analyst estimates of $1.46 billion. Agilon Health had a negative return on equity of 119.38% and a negative net margin of 3.92%.

Here are the key takeaways from Agilon Health’s conference call:

• Agilon raised its 2026 outlook after beating third-quarter guidance, now expecting approximately $5.88 billion in revenue and $150 million in adjusted EBITDA. The stronger outlook reflects higher risk-adjustment revenue and favorable first-half medical cost development, though the company assumes cost trends around 7% for the rest of the year.
• Third-quarter adjusted EBITDA was $64 million, compared with a $91 million loss a year earlier, and the medical services expense ratio improved to 88.5% from 104%. Results benefited from risk-adjustment true-ups, favorable prior-year development, ACO performance, and lower-than-expected medical costs.
• ACO membership is expected to grow approximately 40%–50% in 2027, reaching about 160,000 members, driven largely by expanded MSSP partnerships. Management expects this growth to support improving baseline ACO adjusted EBITDA, while emphasizing a measured approach to new partnerships.
• Medicare Advantage membership was 454,000, down about 10% year over year, reflecting previously announced market exits tied to the company’s profitability-focused contracting strategy. Management also expects 2027 contracting benefits to be more modest than in 2026, when it re-contracted roughly 80% of membership.
• Management cited progress in clinical pathways and quality, including a 3% increase in gap closure and 4.2-star performance on contracted-plan quality measures. It said these programs can improve care and reduce avoidable costs, but noted that implementation and performance still vary across partners.

Agilon Health Stock Up 12.9%

NYSE:AGL traded up $12.42 on Thursday, hitting $108.65. The stock had a trading volume of 265,605 shares, compared to its average volume of 319,508. The business’s fifty day moving average is $87.43 and its 200 day moving average is $65.85. The company has a market cap of $1.82 billion, a PE ratio of -7.63 and a beta of 3.10. The company has a quick ratio of 1.08, a current ratio of 1.08 and a debt-to-equity ratio of 0.07. Agilon Health has a 52 week low of $7.48 and a 52 week high of $133.04.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on the company. Royal Bank Of Canada set a $125.00 price target on Agilon Health in a research note on Tuesday, September 15th. Benchmark reissued a “buy” rating and set a $140.00 target price (up from $95.00) on shares of Agilon Health in a research report on Thursday, August 6th. Sanford C. Bernstein upgraded shares of Agilon Health from a “market perform” rating to an “outperform” rating and raised their price target for the stock from $86.00 to $125.00 in a report on Tuesday, September 15th. Robert W. Baird set a $116.00 price objective on shares of Agilon Health in a research note on Thursday, August 6th. Finally, JPMorgan Chase & Co. upped their price target on shares of Agilon Health from $31.00 to $85.00 and gave the company an “underweight” rating in a research report on Monday, August 24th. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $102.25.

More Agilon Health News

Here are the key news stories impacting Agilon Health this week:

• Positive Sentiment: Agilon reported third-quarter revenue of $1.52 billion, above the roughly $1.46 billion analysts expected. Quarterly earnings were $1.97 per share, sharply ahead of consensus estimates for a loss. The results point to better-than-anticipated performance and are a key near-term catalyst for the stock. Third-quarter results Earnings and revenue estimates comparison
• Positive Sentiment: The company raised its 2026 outlook to $5.88 billion in revenue and $150 million in adjusted EBITDA. It also expects ACO membership to grow 40%–50% in 2027, signaling potential for continued expansion. Updated outlook and membership forecast
• Neutral Sentiment: Agilon will host a virtual investor event on November 17 to discuss its performance framework, with presentations from company executives and a physician partner. The event may provide further detail but is not itself a new financial result. Investor event announcement

Agilon Health Company Profile

Agilon Health, Inc is a healthcare company that partners with independent primary care physicians to support the transition from fee-for-service medicine to value-based care. The company works with physician practices serving primarily older adults enrolled in Medicare Advantage and helps them manage the cost, quality and coordination of care for their patient populations.

Agilon provides a technology-enabled platform that includes population health analytics, clinical and administrative support, care coordination resources and practice-management capabilities.